RI-MUHC ANNUAL REPORT
2016–2017
ADULT AND PEDIATRIC BIOMEDICAL RESEARCH
INNOVATIVE HEALTH CARE DEPENDS ON INNOVATIVE RESEARCH.

At the Research Institute of the McGill University Health Centre, we’re together to innovate!
TABLE OF CONTENTS

3  Message from Bruce Mazer and Raymond Royer
4  Message from Aimee Ryan
5  Message from Martine Alfonso
5  Message from David Eidelman and Martha Crago
6  Year in Review
9  RI-MUHC Leaders and Innovators
15  Business Development Activities
16  Focus on Our Research Trainees
18  Awards and Recognition
19  Salary Awards
20  Publications
24  Funding Summary
26  Oversight
27  Your Support
28  Acknowledgements
427 active members, including 206 fundamental, 134 clinical and 82 evaluative researchers.

1,190 research trainees, including 330 M.Sc. and 490 PhD candidates, 220 postdocs and 150 clinical research fellows.

Over 1,800 peer-reviewed scientific publications.

Over 1,800 ongoing research projects.

Over 2,000 scientific talks given by our researchers worldwide.

39 invention disclosures.

24 patents filed in various countries, corresponding to 17 different inventions.

10 patents issued in various countries, corresponding to 6 different inventions.

28 technology or patent license agreements.

321 research contracts and 640 agreements signed.

Ongoing research collaborations with 51 countries.
Message from
BRUCE MAZER, MD, and RAYMOND ROYER

We have completed Year Two

in our tremendous new facility at the Research Institute of the McGill University Health Centre (RI-MUHC). Like children in their third year, our institute is rapidly developing and growing. Focused on improving performance of our healthcare system through discoveries and innovation, we are also excited due to new faculty joining our programs.

Areas of innovation this year included finalizing an agreement with the Quebec Ministry of Economic Development, Science and Innovation to develop early-phase clinical trials in collaboration with other centres in Quebec.

A grant from the federal Post-Secondary Institutions Strategic Investment Fund, with contributions from the provincial government and Montreal General Hospital Foundation, allows for significant redevelopment of research areas at the Montreal General Hospital (MGH). Plans include new space for the Centre for Outcomes Research and Evaluation, a satellite Centre for Innovative Medicine (our unique clinical trials area), and the Surgical Innovation Platform, our centrepiece for MGH redevelopment. This dedicated incubator for cutting-edge technology will promote interaction among scientists, engineers, lawyers and industry. To these activities we add inventions and other breakthroughs facilitated by the Business Development Office, led by Dr. Costas Karatzas. Several are highlighted in this report.

The remarkable community and facilities at the RI-MUHC have led to renewed interest on the part of young faculty; multiple interviews and new hires are pending. Our research programs have attracted top-flight talent, including investigators in neuroscience, cancer, aging, metabolism, and surgical innovation, with active searches ongoing.

This is by no means a plateau. Group efforts are underway to improve transectorial interactions, creating groups that harness the power of our programs by bringing researchers from multiple disciplines together, creating added value for the RI-MUHC.

We sincerely thank our dedicated members, partners and supporters. To complete the toddler analogy, if we spent our first two years post-move learning to walk, we are now clearly ready to run!
EXECUTIVE MESSAGES

Message from AIMEE RYAN, PhD

Aimee Ryan, PhD
Deputy Executive Director and Deputy Chief Scientific Officer (Interim), Research Institute of the McGill University Health Centre (RI-MUHC)
Head of Child Health Research (Interim), MUHC

The child health research community at the RI-MUHC epitomizes the Together to Innovate theme of this report. Our researchers embrace social media and provide internet resources for patients and families. We use genomics to identify mutations underlying developmental disabilities, congenital anomalies and cancers. We explore innovative methods to improve quality of adult life in individuals treated for childhood diseases: restoring fertility in those treated with chemotherapeutic agents as children, or improving retention of kidney transplants in adolescents transitioning into adulthood.

Child health researchers continue to demonstrate research leadership. Dr. Annette Majnemer co-leads the pan-Canadian CHILD-BRIGHT network, improving life outcomes for children with brain-based developmental disabilities (see p. 6). Dr. Larry Lands’s recommendations for newborn screening for cystic fibrosis have been adopted by the Quebec government, and Dr. Moshe Ben-Shoshan’s research was recognized as one of ten Best Research Publications in Pediatrics for 2016 by the New England Journal of Medicine Publication Watch (pp. 6 and 8).

Our trainees impress with their innovative ideas and many garner national awards, like Marie-Julie Allard from Dr. Guillaume Sébire’s research group, whose autism research earned her recognition by Radio-Canada this year as one of 30 inspirational people under 30. The future of child health research is in good hands as these young scientists move toward independent careers.

We thank The Montreal Children’s Hospital Foundation and staff, who work with community donors and other foundations, including the Foundation of Stars, to support our new investigators and trainees and launch innovative research projects. We look forward to continued research innovation and excellence as fundamental, clinical and evaluative child health researchers at the RI-MUHC work to advance health care and the well-being of children throughout their lives.
EXECUTIVE MESSAGES

Message from the McGill University Health Centre (MUHC)

Martine Alfonso
Interim President and Executive Director, MUHC

As an academic health centre that strives to carry out world-class clinical care, research and teaching in a networked health system, the McGill University Health Centre (MUHC) is proud that the Research Institute of the MUHC (RI-MUHC) has collaborative relationships in Canada and over 50 countries. Through these alliances and its focus on translational research and intervention across the lifespan, the RI-MUHC is having an impact on the health and well-being of people at home and around the globe, while also helping to shape the future of health care. Our commitment to collaborate in the name of progress has also allowed the RI-MUHC to advance knowledge, which in turn has ranked it consistently over the last decade among the top three hospital-based research institutes in Canada.

I am pleased to thank the RI-MUHC’s Interim Executive Director and Chief Scientific Officer, Dr. Bruce Mazer, its researchers and board of directors, as well as foundations, donors and granting agencies for supporting research discoveries and innovation at the MUHC.

Message from McGill University

Research in the health sciences has long been the transformative force solving some of the world’s most pressing challenges, enabling us to discover treatments and cures for deadly diseases. Improving the health of our communities locally, nationally and globally requires a perfect balance among basic, translational and clinical discoveries. Throughout this report are outstanding examples made possible by work conducted at the RI-MUHC. Yet there is still much more we must do to remain at the forefront of a changing health landscape.

McGill is very proud of its longstanding partnership with the RI-MUHC, with which we share a passion for research and commitment to train the best scientists. Today’s early-career researchers represent Canada’s future ability to face the health challenges of the 21st century. State-of-the-art facilities and world-class mentors at the RI-MUHC provide them with an incredibly enriching opportunity to realize their potential and help keep Canada on the map as a global beacon in health science research.

We congratulate colleagues at the RI-MUHC on yet another successful year, and we look forward to continuing to innovate together for the benefit of the populations we serve.

David Eidelman, MD, CM, FRCPC
Vice-Principal (Health Affairs) and Dean, Faculty of Medicine

Martha Crago, PhD
Vice-Principal (Research and Innovation)
FROM DIAGNOSTIC ODYSSEY TO THERAPEUTIC HOPE

Dr. Donald Vinh (Infectious Diseases and Immunity in Global Health Program) specializes in solving medical mysteries by taking clinical observations back to the laboratory bench. His breakthrough in the case of Steven Francis, a patient whose condition had eluded diagnosis for 30 years, was recently published in the *Journal of Allergy and Clinical Immunology*.

Dr. Vinh discovered that Francis harboured a rare genetic mutation that left him immunocompromised and susceptible to recurrent infections. As no treatment for ZAP70 immune deficiency existed, Dr. Vinh’s team developed a molecule that specifically blocked this mutation, restoring immune function and providing hope for future therapy.

ACTIVITY PRESCRIPTIONS: ONE “STEP” CLOSER TO A HEALTHY LIFESTYLE

Dr. Kaberi Dasgupta (Metabolic Disorders and Complications Program) and her team showed that written “step prescriptions” from a physician are associated with improved health outcomes in patients with type 2 diabetes and hypertension.

Their study published in Diabetes, Obesity and Metabolism provided all participants with a pedometer, but only some with a written step count prescription. After one year, patients given the prescription increased their daily counts by 1,200 steps compared to patients not given one, and those with type 2 diabetes showed improved blood sugar control and reduced insulin resistance. It’s a step toward reducing complications of a prevalent chronic disease.
A BRIGHTER FUTURE FOR CHILDREN WITH BRAIN-BASED DEVELOPMENTAL DISABILITIES

The CHILD-BRIGHT Network is a new pan-Canadian research network that aims to improve life outcomes for children with brain-based developmental disabilities and their families.

Principal investigator Dr. Annette Majnemer (Child Health and Human Development Program) leads the network and five-year project with co-directors at The Hospital for Sick Children (SickKids) and the BC Children’s Hospital. She is pioneering patient-oriented programs in research, knowledge translation and training, as well as a citizen engagement platform.

CHILD-BRIGHT is one of seven nationwide networks supported by the Canadian Institutes of Health Research under Canada’s Strategy for Patient-Oriented Research (SPOR). More at www.child-bright.ca.

NEW APPROACH TO DIAGNOSING ANTIBIOTIC ALLERGIES IN CHILDREN

Dr. Moshe Ben-Shoshan (Infectious Diseases and Immunity in Global Health Program) and his team are changing the way we understand childhood antibiotic allergies. They have demonstrated that the traditional method for diagnosing these allergies, based on skin testing, lacks sensitivity.

Graded provocation tests, an alternative method of allergy testing in which children are gradually given the antibiotic, proved to be faster, cheaper and more sensitive than skin testing. Dr. Ben Shoshan’s findings, published in JAMA Pediatrics, demonstrated that skin tests were negative for 94.1% of children who had positive provocation tests for amoxicillin, indicating that skin tests are not appropriate for diagnosing childhood amoxicillin allergies.

NEWBORN SCREENING FOR CYSTIC FIBROSIS IN QUEBEC

Cystic fibrosis (CF) is a respiratory disease characterized by the production of thick mucus that blocks the airways, resulting in chronic infections. Children with CF who are diagnosed through newborn screening are healthier as they can be treated sooner, preventing complications, as Dr. Larry Lands (Translational Research in Respiratory Diseases Program) has demonstrated.

His study published in the Journal of Cystic Fibrosis helped build the case for advocacy of newborn CF screening in Quebec. Thanks to his work and that of other CF Canada members, the Quebec Ministry of Health and Social Services announced in June 2017 that screening will be implemented.
DISCOVERY OF A NOVEL MUTATION LINKED TO HIP OSTEONECROSIS

Osteonecrosis, or “bone death,” occurs when blood flow to the bone is disrupted. In the hip bone, specifically the femoral head, it eventually necessitates hip replacement.

Dr. Chantal Seguin (Injury Repair and Recovery Program) and her team discovered that a novel mutation in a gene called TRPV4 is linked with osteonecrosis. Their breakthrough could shed light on mechanisms driving disease progression, as this gene is known to play important roles in both bone cell development and blood flow regulation. Ultimately, these findings could allow doctors to identify and treat bone death before symptoms arise, and potentially avoid hip replacements.

LIPOPROTEIN(A): A NEW RISK FACTOR IN HEART DISEASE

Dr. George Thanassoulis (Cardiovascular Health Across the Lifespan Program) and his team have demonstrated that a relatively unknown type of cholesterol called Lipoprotein(a), or Lp(a), is associated with increased risk of heart disease. One in 14 heart attacks and one in seven cases of aortic valve disease are due to Lp(a), as their study published in *Arteriosclerosis, Thrombosis and Vascular Biology* reveals.

“We hope our work raises awareness that individuals with high Lp(a) are at high risk of heart disease, and that it stimulates the development and testing of new therapies,” says Dr. Thanassoulis. This highly specialized test is available at the MUHC.

NEW MARKER IDENTIFIED FOR PANCREATIC CANCER

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths, largely because symptoms only become evident once the cancer has progressed to an advanced stage.

Drs. Zu-Hua Gao and George Zogopoulos (Cancer Research Program) and Dr. Jun-Li Liu (Metabolic Disorders and Complications Program) have discovered a new biomarker for this disease, a discovery that outlines quantifiable characteristics of the biological processes.

“We found that PDAC patients had elevated levels of regenerating (Reg) proteins, Reg1A and Reg1B, in their serum and in their cancer tissue,” explains Dr. Gao. “Our findings can help in the early diagnosis of pancreatic cancer, which may improve survival.”
RI-MUHC LEADERS AND INNOVATORS

How can we ensure the right radiation dosage? 
Manage pain?
Use less invasive screening methods?
Optimize positive effects of drugs and reduce the negative?

At the Research Institute of the McGill University Health Centre (RI-MUHC), clinical, fundamental and health outcomes researchers come together to innovate.

With research projects advancing health care across the lifespan, here are some of our leaders who try the paths not yet taken.
Delivering the right dose of radiation for cancer patients

For Dr. Jan Seuntjens, a member of the Cancer Research Program at the Research Institute of the McGill University Health Centre (RI-MUHC), it all begins and ends with the patient. “All of my research questions come from the clinic,” explains the medical physicist, whose work revolves around techniques to ensure accurate radiation dosage in cancer therapy. Recently, postdoctoral fellow Dr. James Renaud, working with Dr. Seuntjens and a collaborator, Dr. Arman Sarfehnia (Sunnybrook, Toronto), discovered a way to miniaturize a calorimetric-based radiation detector from something the size of a fridge to a pencil-sized probe named the Aerrow. The technology has been sold to an American company now working with Dr. Seuntjens’ group and with a Quebec-based engineering firm to bring the probe to market.

This is not the only project from the physicist’s lab heading for clinical application. Dr. Seuntjens’ doctoral student, Marc-André Renaud, and colleague Dr. François DeBlois (Centre hospitalier de l’Université de Montréal) developed a software system that uses a computational algorithm based on the Monte Carlo technique to determine radiation dose. The software, Radify, uses a computed tomography scan of the patient to calculate the amount of radiation energy absorbed by the tissues. Purchased, as Aerrow was, by an American company, Radify will be used for quality assurance of radiation therapy delivery.

These contracts are a coup for the research group, but Dr. Seuntjens’ main goal is to get the technology to market where it can be used to benefit patients.

Assessing radiation modelling accuracy: Jan Seuntjens, PhD (right), and student, Marc-André Renaud

—Dr. Jan Seuntjens
Mapping pathways in drug response

Roughly 40% of drugs currently on the market—from beta-blockers to opioids—target a class of membrane proteins found in the human genome that are known as G protein-coupled receptors (GPCRs).

More than 800 GPCRs control all kinds of processes throughout the human body, says Dr. Stéphane Laporte, a member of the Metabolic Complications and Disorders Program and Director of the Molecular Imaging Platform at the RI-MUHC. However, few of these GPCRs are well understood, and drugs act in diverse ways on those that are known.

Dr. Laporte and his team are working to change this by focusing on understanding the molecular and cellular mechanisms that regulate GPCRs. “The receptors act on different signalling pathways in the cell, and we can activate them, or block them, in different ways,” he says.

He and his colleagues, including Dr. Michel Bouvier of the Institute for Research in Immunology and Cancer, Université de Montréal, have developed biosensors that can be used to “light up” the different pathways in living cells. The hope, for drug companies, is that if they know which pathways to target, they can find a drug that produces the desired beneficial effects without the negative effects: for example, an opioid that relieves pain without causing tolerance, respiratory depression or constipation, says Dr. Laporte.

The novel technology has already been licensed by several therapeutic and pharmaceutical companies, and Dr. Laporte expects that new and improved medications will be available in the next five to ten years.

The hope, for drug companies, is that if they know which pathways to target, they can find a drug that produces the desired beneficial effects without the negative effects.
AN INFORMED APPROACH TO MEDICAL CANNABIS USAGE

Learning from patients in pain

“I focus on trying to take an integrative and scientific approach to a product like cannabis, which is widely used and widely misunderstood,” says Dr. Mark Ware (Brain Repair and Integrative Neuroscience Program; Centre for Outcomes Research and Evaluation).

A family physician who works in chronic pain, Dr. Ware was initially inspired to research the use of cannabis for pain management after hearing anecdotal evidence of its potential from his patients. Although he has been doing this research for some 17 years, Dr. Ware, vice-chair of the recent Canadian federal task force on cannabis legalization and regulation, cautions that there is still a lot to learn.

“Clinical research needs patients and patience,” he says, and cannabis research tends to take longer because the regulatory pathways are quite new. “We are forging paths that have not been taken, and asking questions that have not been asked before,” he explains.

Dr. Ware is principal investigator of the Quebec Cannabis Registry, the world’s first research database on the use of cannabis for medical purposes, and he is excited by the potential of the database to answer some of these questions. “As of today we are about halfway to our target enrolment of 3,000 patients,” he reports. He is hopeful that by late 2017, the registry will have a dataset clean enough to ask some preliminary questions.
A counterintuitive approach to COPD management

It all began with questions from patients with chronic obstructive pulmonary disease (COPD) who were participating in a clinical trial for oral morphine. A few wondered whether anyone was doing research into cannabis for the management of breathlessness. The idea seemed counterintuitive, says Dr. Dennis Jensen (Translational Research in Respiratory Diseases Program; Centre for Innovative Medicine), but once he and his team looked at the literature, they realized there might be something to it.

In a series of studies done about 40 years ago, “there was some evidence that smoked cannabis actually improved acute lung function in healthy adults and in patients with asthma,” he explains.

Dr. Jensen and colleagues, including Dr. Jean Bourbeau, Director of the Centre for Innovative Medicine, and Dr. Mark Ware, reached out to the medical marijuana company Tilray and proposed a pilot randomized clinical trial to look at the effect of cannabis on pulmonary function, breathlessness and exercise tolerance in patients with COPD.

The patients in the trial all had advanced COPD and suffered from disabling breathlessness, despite receiving optimal available medication for their disease. They were given inhaled vaporized cannabis or a placebo, followed by a series of lung function tests and a cardiopulmonary cycle exercise endurance test. The trial has been completed with results pending publication.

“This is truly the first trial in the world to look at this in COPD,” says Dr. Jensen. “And this trial is just the first step.”

Jean Bourbeau, MD, M.Sc., and Dennis Jensen, PhD

Dr. Jensen explains the administration of inhaled vaporized cannabis.
A NONINVASIVE TEST FOR CHILDREN WITH KIDNEY DISEASE

“The most common cause of kidney failure in children is from a kidney connected to a malformed drainage system,” says pediatric nephrologist Dr. Indra Gupta (Child Health and Human Development Program; Centre for Translational Biology).

Currently, to diagnose this kind of drainage defect, physicians must insert a catheter in the child’s urethra, fill the bladder with contrast dye, and then use radiation-based imaging technology. “It’s not very pleasant for the children, or for the parents,” says Dr. Gupta. She is hopeful, however, that there will eventually be a much simpler test for the children that can be performed at the bedside.

Dr. Gupta and her colleagues identified a gene—tenascin XB—associated with the development of support tissues in the drainage system as well as other areas of the body.

“Children who have mutations in this gene have a defect in their drainage system and they get frequent urine infections,” she explains. “Our work has determined that these children are also double-jointed or very flexible, probably because there are also defects in the support tissues around the joints.”

Indra Gupta, MD, a pediatric clinician-scientist, finds solutions for her young patients with kidney disease

This led the research team to investigate a simple test for hypermobility that involves asking children to manipulate their joints, in order to further identify those at risk for drainage problems. Dr. Gupta and her colleagues are currently using this screening method to test children suspected of being at risk of drainage problems in hopes of confirming the association. “And the children actually enjoy doing it!” she says.
NEW TARGET FOR CYSTIC FIBROSIS
DRUG DEVELOPMENT: CERAMIDES

Cystic fibrosis (CF) is a deadly respiratory disease characterized by thick mucus in the lungs. This mucus becomes colonized by pathogens and initiates a vicious cycle of infection and inflammation. Although no effective therapeutic options for CF exist, Dr. Danuta Radzioch (Infectious Diseases and Immunity in Global Health Program) and her research team have made important advances with the help of industry.

The team discovered that ceramides—a specialized type of lipids found in human cells—are imbalanced in the lungs of CF patients. Ceramides are involved in triggering immune responses necessary to combat infections. Thus, severely imbalanced ceramide levels are associated with an inability to mount an effective immune response against these pathogens. The team further demonstrated that administration of the drug fenretinide can restore normal levels of protective ceramides in CF patients.

“CF patients are often treated with corticosteroids, but these drugs suppress the immune system and impede its ability to fight infection,” explains Dr. Radzioch. “What makes fenretinide so exciting is that, in contrast to corticosteroids, correcting ceramide imbalance actually improves the ability of the immune system to combat pathogens.”

These groundbreaking findings from the Phase Ib trial were published in the *Journal of Molecular Medicine*, and Laurent Pharmaceuticals Inc. is sponsoring a Phase II clinical trial.

The development of fenretinide for the treatment of CF depended on dedicated collaborators, says Dr. Radzioch, including *Drs. Elias Matouk* and *Larry Lands* (Translational Research in Respiratory Diseases Program), the McGill Office of Technology Transfer, industry partners, and *Dr. Costas Karatzas*, Director of the Business Development Office at the Research Institute of the McGill University Health Centre. “This ongoing team effort enabled us to protect critical patents, secure funding opportunities and partner with a private company so that our research could transition through pre-clinical and early clinical trials, with the ultimate goal of benefiting CF patients,” she explains.
FOCUS ON OUR RESEARCH TRAINEES

Nearly 1,200 research trainees provide a wealth of new ideas at the Research Institute of the McGill University Health Centre (RI-MUHC). These are only a few.

Students

RENATA BAHOUS
DOCTORAL CANDIDATE
Supervisor: Dr. Rima Rozen
Child Health and Human Development Program
GENETIC DEFICIENCIES IN THE METABOLISM OF FOLIC ACID
• FRQS award
• Showed high levels of folic acid in pregnant mice leads to short-term memory impairment in offspring (Human Molec Genet. 2017). Suggests that pregnant women should consume modest amounts of folic acid
• Two publications; seven presentations with three awards

CLAIRE GIZOWSKI
DOCTORAL CANDIDATE
Supervisor: Dr. Charles Bourque, Brain Repair and Integrative Neuroscience Program
THIRST, OSMOREGULATION, CIRCADIAN RHYTHMS, NEUROTRANSMISSION
• Recipient of the first Carbonetto Award from the Centre for Research in Neuroscience
• First-author publication in Nature

KASHIF KHAN
M.Sc. CANDIDATE
Supervisor: Dr. Renzo Cecere, Cardiovascular Health Across the Lifespan Program
HEART TISSUE REGENERATION, ANGIGENESIS, STEM CELL, HIPPO CELL FACTOR
• First prize: Annual 3-Minute Thesis (3MT) competition, McGill University
• First prize and People’s Choice Award: 2017 Eastern Regional 3-Minute Thesis Competition, University of New Brunswick

EMERSON KROCK, PhD
DOCTORAL CANDIDATE IN 2016-2017
Supervisor: Dr. Lisbet Haglund, Injury Repair Recovery Program
BACK PAIN
• FRQS doctoral award (three years) and two additional fellowships
• Five publications to date, three as first author
• Awarded best oral presentation at World Forum for Spine Research in Xi’an, China, May 2014
FOCUS ON OUR RESEARCH TRAINEES

Postdoctoral Fellows

DORIVAL MARTINS, PhD
Supervisor: Dr. Dao Nguyen, Translational Research in Respiratory Diseases Program
BIOCHEMISTRY, MOLECULAR BIOLOGY AND CHEMICAL PHYSIOLOGY OF ANTIBIOTIC TOLERANCE
- CIHR Postdoctoral Fellowship
- Awards: Gordon Research Conference, Cystic Fibrosis European Meeting, RI-MUHC Respiratory Research Day
- One first-author publication, five in preparation; one report of invention
- Featured research in media: Cystic Fibrosis Canada
- Postdoctoral Career Day organizer
- Trainee committee: FRQS visit preparations

CLAIRE NASH, PhD
Supervisor: Dr. Axel Thomson, Cancer Research Program
PROSTATE, STROMA, MESENCHYME, ANDROGEN RECEPTOR, PRIMARY CELLS, CANCER-ASSOCIATED FIBROBLASTS
- First and third author of two publications in Molecular and Cellular Endocrinology in 2017
- First prize for oral presentations: Cancer Research Program Research Day 2017, RI-MUHC; Fraser Gurd Research Day 2017, Experimental Surgery, McGill University

JESSICA WIDDIFIELD, PhD
Supervisor: Dr. Sasha Bernatsky, Infectious Diseases and Immunity in Global Health Program
EVALUATING PATIENT CARE AND OUTCOMES OF RHEUMATOID ARTHRITIS
- Six peer-reviewed publications (first author of four) since 2016
- Ten abstracts/presentations at local, national and international scientific meetings
- CIHR/Arthritis Alliance of Canada Postdoctoral Prize recipient
- Lead or co-lead on five successful grant applications, with four more under review

LAMA YAMANI, PhD
Supervisor: Dr. Stéphane Laporte, Experimental Therapeutics and Metabolism Program
DEVELOPING AND VALIDATING BIOSENSORS AS TOOLS FOR IDENTIFYING BETTER DRUGS
- Postdoctoral Training Fellowship, Mitacs Accelerate Program in partnership with Domain Therapeutics
- Third prize poster presentation, International Drug Discovery and Development Forum in Montreal, June 2017
- Authored five publications in high-impact journals, including co-authorship in Nature Communications in 2017
AWARDS AND RECOGNITION

Marcel Behr, MD, M.Sc.
Fellow, Canadian Academy of Health Sciences

Moshe Ben-Shoshan, MD

Christine McCusker, MD, M.Sc.
F. Estelle R. Simons Award for Research, Canadian Society of Allergy and Clinical Immunology

Raquel del Carpio-O’Donovan, MD
Gold Medal, Canadian Association of Radiologists
Gold Medal, Peruvian Radiology Society and InterAmerican College of Radiology

Theresa Gyorkos, PhD
Vic Neufeld Mentorship Award in Global Health Research, Canadian Coalition for Global Health Research

Jim Hanley, PhD
Statistical Society of Canada Impact Award

Bruce Mazer, MD
Jerry Dolovich Award, Canadian Society of Allergy and Clinical Immunology

Martin Olivier, PhD
Wardle Medal, Canadian Society of Zoologists

Nitika Pant Pai, MD, PhD
“Transition-to-scale” support, Grand Challenges Canada

Morag Park, PhD
Robert L. Noble Prize, Canadian Cancer Society

Louise Pilote, MD, PhD
Woman of Distinction Award, Health category, YWCA

Danuta Radzioch, PhD
Co-investigator, study selected as People’s Choice, Top 10 Discoveries of 2016, *Québec Science* magazine

David Stellwagen, PhD
Discovery Accelerator Supplement, Natural Sciences and Engineering Research Council

Patricia Tonin, PhD
Karen Campbell Award for Research Excellence, Ovarian Cancer Canada

Mark Ware, MD, M.Sc.
Vice-chair, federal Task Force on Cannabis Legalization and Regulation

FELLOWS OF THE ROYAL SOCIETY OF CANADA
Charles Bourque, PhD
William Foulkes, MD, PhD
Guy Rouleau, MD, PhD

OUTSTANDING ACHIEVEMENTS RECOGNIZED BY MCGILL UNIVERSITY
Sara Ahmed, PhD
Steven Backman, MD, PhD
John Bergeron, PhD
Stella Daskalopoulou, MD, PhD
William Foulkes, MD, PhD
Marina Klein, MD, M.Sc.
Nancy Mayo, PhD
Emil Nashi, MD, PhD
Madhukar Pai, MD, PhD
Maya Saleh, PhD
FONDS DE RECHERCHE DU QUÉBEC SANTÉ (FRQS)

RESEARCH CHAIRS
Nada Jabado
Edward Ruthazer

NATIONAL RESEARCHERS
Marina Klein
Robert William Platt

RESEARCH SCHOLARS
Carolyn Baglole
Sylvain Balilat
Andrea Benedetti
Sasha Bernatsky
Jean-François Cloutier
Nandini Dendukuri
Mazzar Divangahi
Elena Dragomir
Mayada Elsabbagh
Reza Farivar-Mohseni
Lesley Fellows
Dennis Jensen
Neda Ladbon-Bernasconi
Jacques Lapointe
Christine Maheu
Monzur Mushref
Cristian O’Flaherty
Christopher Pack
Nitika Pant Pai
Simon Rousseau
Maya Saleh
Don Sheppard

CLINICAL RESEARCH SCHOLARS
Jonathan Afilalo
Rajesh Aggarwal
Faiz Ahmad Khan
Sero Andonian
Moshe Ben-Shoshan
Geneviève Bernard
Ines Colmegna
Evelyn Constantin
Kaberi Dasgupta
Stella Daskalopoulos
Simon Ducharme
Vidal Essebag
Lorenzo Ferri
Patricia Fontela
Bethany Foster
Matthias Friedrich
Isabelle Gagnon
Anne Gonzalez
Wassim Kassouf
Arnold Kristof
Bertrand Lebouché
Virginia Lee
Ariane Marelli
Paul Martineau
Suzanne Morin
Meranda Nakhla
Dao Nguyen
Maryam Oskoui
Sushmita Pamidi
Jesse Papenburg
Kevin Petrecca
Ronald Postuma
Caroline Quach-Thanh
Frank Rauch
Janet E. Rennick
Stéphane Rinfret
Michael Sebag
Giada Sebastiani
Jason Shahin
Yoanna Skrobik
Benjamin Smith
Myriam Sour
George Thanassoulis
Evelyne Vinet
Donald Vinh
Michael Weber
Pia Wintermark
Cedric Yansouni
Michele Zappitelli
George Zogopoulos

SALARY AWARDS

CANADIAN INSTITUTES OF HEALTH RESEARCH (CIHR)

CANADA RESEARCH CHAIRS

TIER 1
Bartha Maria Knoppers
Mark Lathrop
Leonard A. Levin
Heidi McBride
William Muller
Madhukar Pai
Vassilios Papadopoulos
Guy Rouleau
Ernest Seidman
Silvia Vidal

TIER 2
Brian Chen
Kolja Eppert
Ahmad Haidar
Dennis Jensen
Tomi Pastinen
Petra Schweinhardt
Amir Shmuel

APPLIED PUBLIC HEALTH CHAIR
David Buckeridge

CHAIR: GLAXOSMITHKLINE PARTNERED
Jean Bourbeau

CIHR CLINICIAN SCIENTIST
Etienne de Villers-Sidani

NEW INVESTIGATOR
Jonathan Afilalo
Geneviève Bernard
Patricia Li
Per Jesper Sjöström
Robert Sladek

KRESCENT NEW INVESTIGATOR
Ruth Sapir-Pichhadze

MCGILL UNIVERSITY

JAMES MCGILL PROFESSOR
Michal Abrahamowicz
Douglas Arnold
Chawki Benkelfat
Charles W. Bourque
Alan Evans
William Foulkes
Quatayba Hamid
Sabah Hussain
Michael Kramer
Nancy Mayo
Alain Nepeu
Morag Park
Michael Petrides
Louise Pilote
Bernard Robaire
Rima Rozen
Jan Seuntiens
Eric Shoubridge
Wayne Sossin
Stefano Stifani
Robyn Tamblyn
Jacqueta Trasler
Robert Zatorre

WILLIAM DAWSON SCHOLAR
Jacek Majewski
Peter Siegel

KILLAM SCHOLAR
Sylvain Baillet
Bernard Bras
Etienne de Villers Sidani
Neda Ladbon-Bernasconi
Heidi McBride
Andrew Reader
Amir Shmuel
Hiroshi Tsuda
SELECTED FROM OVER 1,800 PEER-REVIEWED PUBLICATIONS

Investigators | Research trainees

---

**INJURY REPAIR RECOVERY PROGRAM**


**METABOLIC DISORDERS AND COMPLICATIONS PROGRAM**


**INFECTIOUS DISEASES AND IMMUNITY IN GLOBAL HEALTH PROGRAM**

Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic...


CANCER RESEARCH PROGRAM


CANCER RESEARCH PROGRAM


## Funding Summary

### Institutional Grants

<table>
<thead>
<tr>
<th>Source</th>
<th>2016-2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fonds de recherche du Québec–Santé (FRQS)</td>
<td>$4,411,972</td>
</tr>
<tr>
<td>Research Support Fund (Government of Canada)</td>
<td>$4,535,471</td>
</tr>
<tr>
<td>McGill University Health Centre (MUHC) Foundations</td>
<td>$1,405,703</td>
</tr>
<tr>
<td>Other revenues</td>
<td>$5,590,671</td>
</tr>
<tr>
<td>Canada Foundation for Innovation—Research Hospital Fund</td>
<td>$33,659,144</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$49,602,961</strong></td>
</tr>
</tbody>
</table>

### Research Projects

<table>
<thead>
<tr>
<th>Source</th>
<th>2016-2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canadian Institutes of Health Research (CIHR)</td>
<td>$51,707,838</td>
</tr>
<tr>
<td>Industry</td>
<td>$18,292,577</td>
</tr>
<tr>
<td>Other (various granting agencies)</td>
<td>$15,528,744</td>
</tr>
<tr>
<td>MUHC (including Foundations) and McGill University</td>
<td>$12,393,978</td>
</tr>
<tr>
<td>Génome Québec and Genome Canada</td>
<td>$9,157,197</td>
</tr>
<tr>
<td>Canada Foundation for Innovation</td>
<td>$9,030,989</td>
</tr>
<tr>
<td>Fonds de recherche du Québec–Santé (FRQS)</td>
<td>$6,605,406</td>
</tr>
<tr>
<td>Natural Sciences and Engineering Research Council of Canada</td>
<td>$4,470,568</td>
</tr>
<tr>
<td>Brain Canada Foundation</td>
<td>$4,360,311</td>
</tr>
<tr>
<td>Ministère de l’Éducation et de l’Enseignement supérieur du Québec</td>
<td>$3,654,588</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>$3,361,809</td>
</tr>
<tr>
<td>Canada Research Chairs</td>
<td>$2,600,000</td>
</tr>
</tbody>
</table>

## Our Worldwide Network

Ongoing research collaborations with **51** countries.

- CANADA
- USA
- CUBA
- PERU
- BRAZIL
- CHILE
### RESEARCH PROJECTS CONT’D

<table>
<thead>
<tr>
<th>Organization</th>
<th>Funding 2016-2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Department of Defense</td>
<td>$2,555,414</td>
</tr>
<tr>
<td>Consortium québécois sur la découverte du médicament</td>
<td>$1,331,492</td>
</tr>
<tr>
<td>Terry Fox Foundation</td>
<td>$1,072,107</td>
</tr>
<tr>
<td>Networks of Centres of Excellence of Canada</td>
<td>$855,708</td>
</tr>
<tr>
<td>Canadian Partnership Against Cancer</td>
<td>$838,722</td>
</tr>
<tr>
<td>Multiple Sclerosis Society of Canada</td>
<td>$806,962</td>
</tr>
<tr>
<td>Costello Bequest Foundation</td>
<td>$673,366</td>
</tr>
<tr>
<td>Public Health Agency of Canada</td>
<td>$671,104</td>
</tr>
<tr>
<td>Canadian Cancer Society Research Institute</td>
<td>$624,279</td>
</tr>
<tr>
<td>PROCURE—The Force Against Prostate Cancer</td>
<td>$539,766</td>
</tr>
<tr>
<td>Cystic Fibrosis Canada</td>
<td>$524,438</td>
</tr>
<tr>
<td>Prostate Cancer Canada</td>
<td>$499,105</td>
</tr>
<tr>
<td>MITACS</td>
<td>$487,999</td>
</tr>
<tr>
<td>Quebec Breast Cancer Foundation</td>
<td>$430,355</td>
</tr>
<tr>
<td>Richard and Edith Strauss Canada Foundation</td>
<td>$400,000</td>
</tr>
<tr>
<td>Michael J. Fox Foundation</td>
<td>$387,049</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis (ALS) Society of Canada</td>
<td>$356,219</td>
</tr>
<tr>
<td>European Commission</td>
<td>$352,883</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$154,570,972</strong></td>
</tr>
</tbody>
</table>

### TOTAL FUNDING

| Total Funding 2016-2017 | $204,173,933 |

---

**FINDING SUMMARY**

**RESEARCH PROJECTS CONT’D**

<table>
<thead>
<tr>
<th>Organization</th>
<th>Funding 2016-2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Department of Defense</td>
<td>$2,555,414</td>
</tr>
<tr>
<td>Consortium québécois sur la découverte du médicament</td>
<td>$1,331,492</td>
</tr>
<tr>
<td>Terry Fox Foundation</td>
<td>$1,072,107</td>
</tr>
<tr>
<td>Networks of Centres of Excellence of Canada</td>
<td>$855,708</td>
</tr>
<tr>
<td>Canadian Partnership Against Cancer</td>
<td>$838,722</td>
</tr>
<tr>
<td>Multiple Sclerosis Society of Canada</td>
<td>$806,962</td>
</tr>
<tr>
<td>Costello Bequest Foundation</td>
<td>$673,366</td>
</tr>
<tr>
<td>Public Health Agency of Canada</td>
<td>$671,104</td>
</tr>
<tr>
<td>Canadian Cancer Society Research Institute</td>
<td>$624,279</td>
</tr>
<tr>
<td>PROCURE—The Force Against Prostate Cancer</td>
<td>$539,766</td>
</tr>
<tr>
<td>Cystic Fibrosis Canada</td>
<td>$524,438</td>
</tr>
<tr>
<td>Prostate Cancer Canada</td>
<td>$499,105</td>
</tr>
<tr>
<td>MITACS</td>
<td>$487,999</td>
</tr>
<tr>
<td>Quebec Breast Cancer Foundation</td>
<td>$430,355</td>
</tr>
<tr>
<td>Richard and Edith Strauss Canada Foundation</td>
<td>$400,000</td>
</tr>
<tr>
<td>Michael J. Fox Foundation</td>
<td>$387,049</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis (ALS) Society of Canada</td>
<td>$356,219</td>
</tr>
<tr>
<td>European Commission</td>
<td>$352,883</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$154,570,972</strong></td>
</tr>
</tbody>
</table>

**TOTAL FUNDING**

| Total Funding 2016-2017 | **$204,173,933** |

---

**FINDING SUMMARY**
## OVERSIGHT

### BOARD OF DIRECTORS

- Raymond Royer  
  Chair
- Louise Proulx  
  Vice-Chair
- Pierre Lortie  
  Treasurer
- Cinzia Raponi  
  Secretary
- Martine Alfonso
- Graham Bagnall
- Jacques Dupuis
- David Eidelman
- William Fraser
- Daniel Gagnier
- Rose Goldstein
- Bruce Mazer
- Vassilios Papadopoulos
- Normand Rinfret
- Nicolas Steinmetz

### CENTRE DIRECTORS

- Jean Bourbeau  
  Centre for Innovative Medicine
- Michael Kramer  
  Centre for Outcomes Research and Evaluation
- Donald van Meyel  
  Centre for Translational Biology

### SCIENTIFIC ADVISORY COMMITTEE (2016)

- Mark Batshaw  
  Executive Vice President, Physician-in-Chief & Chief Academic Officer, Children’s National Health System (US)
- Kris Chadee  
  Professor of Microbiology, Immunology & Infectious Diseases, University of Calgary
- Jim Woodgett  
  Director of Research, Lunenfeld-Tanenbaum Research Institute
- David Hill  
  Scientific Director, Lawson Health Research Institute
- Albert Descoteaux  
  Professor and Director, McGill Centre for Host-Parasite Interactions
- Philippe Walker  
  General Manager of R&D and Chief Scientific Officer, NEOMED Institute

### SCIENTIFIC LEADERSHIP COMMITTEE

- Bruce Mazer  
  Chair
- Jenny Koulis  
  Secretary
- Jean Bourbeau
- Edward Harvey
- Costas Karatzas
- Michael Kramer
- Ariane Marelli
- Peter Metrakos
- Keith Murai
- Basil Petrof
- Constantin Polychronakos
- Erwin Schurr
- Simon Wing
- Donald van Meyel

### AUDIT/INVESTMENT COMMITTEE

- Pierre Lortie  
  Chair
- Cinzia Raponi  
  Secretary
- Graham Bagnall
- Stéphane Beaudry
- Jaime Fimstone
- Louise Proulx
- Bruce Mazer

### MANAGEMENT COMMITTEE

- Bruce Mazer  
  Chair from Oct. 2016
- Vassilios Papadopoulos  
  Chair until Sept. 2016
- Jenny Koulis  
  Secretary
- Jean Bourbeau
- Miguel Burnier
- David Eidelman
- Gerald Fried
- Philippe Gros
- Costas Karatzas
- Michael Kramer
- James Martin
- Cinzia Raponi
- Aimee Ryan
- Michael Shevell
- Donald van Meyel
- Simon Wing

### RESEARCH PROGRAM COUNCIL

- Simon Wing  
  Chair
- Basil Petrof  
  Vice-Chair
- Jenny Koulis  
  Secretary
- Jean Bourbeau
- Miguel Burnier
- Gerald Fried
- Ed Harvey
- Costas Karatzas
- Michael Kramer
- Virginia Lee
- Ariane Marelli
- James Martin
- Bruce Mazer
- Peter Metrakos
- Keith Murai
- Vassilios Papadopoulos
- Kim Phan*
- Constantin Polychronakos
- Cinzia Raponi
- Amanda Rossi *
- Aimee Ryan
- Erwin Schurr
- Michael Shevell
- Donald van Meyel
*Trainee Council representatives

### SPACE MANAGEMENT COMMITTEE

- Donald van Meyel  
  Chair
- Jean Bourbeau
- Jean-Marie Chavannes
- Jean Ghannoun
- Susan James
- Daniele Karam
- Michael Kramer
- Vassilios Papadopoulos
- Bruce Mazer
- Cinzia Raponi

### EXECUTIVE OPERATIONS COMMITTEE

- Bruce Mazer  
  Chair from Oct. 2016
- Vassilios Papadopoulos  
  Chair until Sept. 2016
- Carolina Mancini  
  Secretary
- Jean-Marie Chavannes
- Lucie Coté
- Susan James
- Costas Karatzas
- Danika Laberge
- Dorothy McKelvey
- Jaime Fimstone
- Cinzia Raponi
- Sonia Rea
At the Research Institute of the McGill University Health Centre (RI-MUHC), our innovations bring real change to health care.

More than a research hospital: A hospital driven by research!

We are deeply grateful to our foresighted donors and volunteers, and to the foundations and auxiliaries affiliated with the McGill University Health Centre (MUHC). Together, we have the means to leverage discovery aimed at improving the health of individual patients across their lifespan.

We also thank provincial, federal and other funding partners, including the Canada Foundation for Innovation, the Fonds de recherche du Québec–Santé and the Ministère de la Santé et des Services sociaux. Their support remains a key driver of our success.

CEDARS CANCER FOUNDATION
McGILL UNIVERSITY HEALTH CENTRE FOUNDATION
MONTREAL CHILDREN’S HOSPITAL FOUNDATION

MONTREAL GENERAL HOSPITAL FOUNDATION
ROYAL VICTORIA HOSPITAL FOUNDATION
THE AUXILIARY OF THE MONTREAL GENERAL HOSPITAL

YOUR SUPPORT

DISCOVERY CLUB

Doctors have the power to heal… but researchers have the power to cure

Be part of the discovery!
“Your support can help our researchers change the outcome of an illness—potentially for someone you love.”—Dr. Bruce Mazer

ACKNOWLEDGEMENTS

The 2016–2017 Annual Report was produced by Alison Burch of the Internal Communications Department, Research Institute of the McGill University Health Centre (RI-MUHC).

A special thanks to all the members across the RI-MUHC and the MUHC for their collaboration, time and inspiration.

CONTRIBUTORS

PHOTOGRAPHY
Pierre Dubois, Medical Multimedia Services, MUHC
Owen Egan
Loïc Pravaz, www.pravaz.com

GRAPHIC DESIGN
Ildiko A. Horvath
Linda Jackson
Medical Multimedia Services, MUHC

PRINTING
Le Groupe Quadriscan

FREELANCE WRITING
Necola Guerrina
Maria Turner

TRANSLATION
Catherine Jalbert

Research Institute of the McGill University Health Centre (RI-MUHC)
2155 Guy St., 5th floor
Montreal, Quebec, Canada H3H 2R9
rimuhc.ca

© Copyright 2017. All rights reserved.